Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 3
2011 4
2012 4
2013 2
2016 2
2017 5
2018 3
2019 4
2020 3
2021 5
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Virus-Vectored Ebola Vaccines.
Dolzhikova IV, Tokarskaya EA, Dzharullaeva AS, Tukhvatulin AI, Shcheblyakov DV, Voronina OL, Syromyatnikova SI, Borisevich SV, Pantyukhov VB, Babira VF, Kolobukhina LV, Naroditsky BS, Logunov DY, Gintsburg AL. Dolzhikova IV, et al. Among authors: tukhvatulin ai. Acta Naturae. 2017 Jul-Sep;9(3):4-11. Acta Naturae. 2017. PMID: 29104771 Free PMC article.
Toll-like receptors and their adapter molecules.
Tukhvatulin AI, Logunov DY, Shcherbinin DN, Shmarov MM, Naroditsky BS, Gudkov AV, Gintsburg AL. Tukhvatulin AI, et al. Biochemistry (Mosc). 2010 Sep;75(9):1098-114. doi: 10.1134/s0006297910090038. Biochemistry (Mosc). 2010. PMID: 21077829 Review.
Development of adenoviral vector-based mucosal vaccine against influenza.
Tutykhina IL, Logunov DY, Shcherbinin DN, Shmarov MM, Tukhvatulin AI, Naroditsky BS, Gintsburg AL. Tutykhina IL, et al. Among authors: tukhvatulin ai. J Mol Med (Berl). 2011 Apr;89(4):331-41. doi: 10.1007/s00109-010-0696-0. Epub 2010 Nov 21. J Mol Med (Berl). 2011. PMID: 21104066 Review.
Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study.
Tukhvatulin AI, Dolzhikova IV, Dzharullaeva AS, Grousova DM, Kovyrshina AV, Zubkova OV, Zorkov ID, Iliukhina AA, Shelkov AY, Erokhova AS, Popova O, Ozharovskaia TA, Zrelkin DI, Izhaeva FM, Shcheblyakov DV, Esmagambetov IB, Tokarskaya EA, Nikitenko NA, Lubenets NL, Khadorich EA, Gushchin VA, Borzakova SN, Vlasova AV, Osmanov IM, Gorev VV, Naroditsky BS, Logunov DY, Gintsburg AL. Tukhvatulin AI, et al. Front Immunol. 2023 Aug 1;14:1228461. doi: 10.3389/fimmu.2023.1228461. eCollection 2023. Front Immunol. 2023. PMID: 37600800 Free PMC article. Clinical Trial.
Nanobodies Are Potential Therapeutic Agents for the Ebola Virus Infection.
Esmagambetov IB, Shcheblyakov DV, Egorova DA, Voronina OL, Derkaev AA, Voronina DV, Popova O, Ryabova EI, Shcherbinin DN, Aksenova EI, Semenov AN, Kunda MS, Ryzhova NN, Zubkova OV, Tukhvatulin AI, Logunov DY, Naroditsky BS, Borisevich SV, Gintsburg AL. Esmagambetov IB, et al. Among authors: tukhvatulin ai. Acta Naturae. 2021 Oct-Dec;13(4):53-63. doi: 10.32607/actanaturae.11487. Acta Naturae. 2021. PMID: 35127147 Free PMC article.
Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals.
Lapa D, Grousova DM, Matusali G, Meschi S, Colavita F, Bettini A, Gramigna G, Francalancia M, Garbuglia AR, Girardi E, Puro V, Antinori A, Kovyrshina AV, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Gushchin VA, Logunov DY, Naroditsky BS, Vaia F, Gintsburg AL. Lapa D, et al. Among authors: tukhvatulin ai. Vaccines (Basel). 2022 May 21;10(5):817. doi: 10.3390/vaccines10050817. Vaccines (Basel). 2022. PMID: 35632574 Free PMC article.
Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus Infection.
Voronina DV, Shcheblyakov DV, Favorskaya IA, Esmagambetov IB, Dzharullaeva AS, Tukhvatulin AI, Zubkova OV, Popova O, Kan VY, Bandelyuk AS, Shmarov MM, Logunov DY, Naroditskiy BS, Gintsburg AL. Voronina DV, et al. Among authors: tukhvatulin ai. Viruses. 2022 Nov 10;14(11):2485. doi: 10.3390/v14112485. Viruses. 2022. PMID: 36366583 Free PMC article.
Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period.
Fomina DS, Lebedkina MS, Iliukhina AA, Kovyrshina AV, Shelkov AY, Andreev SS, Chernov AA, Dolzhikova IV, Kruglova TS, Andrenova GV, Tukhvatulin AI, Shcheblyakov DV, Karaulov AV, Lysenko MA, Logunov DY, Gintsburg AL. Fomina DS, et al. Among authors: tukhvatulin ai. Front Immunol. 2023 Oct 20;14:1259725. doi: 10.3389/fimmu.2023.1259725. eCollection 2023. Front Immunol. 2023. PMID: 37928549 Free PMC article. Clinical Trial.
Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates.
Tukhvatulin AI, Gordeychuk IV, Dolzhikova IV, Dzharullaeva AS, Krasina ME, Bayurova EO, Grousova DM, Kovyrshina AV, Kondrashova AS, Avdoshina DV, Gulyaev SA, Gulyaeva TV, Moroz AV, Illarionova VV, Zorkov ID, Iliukhina AA, Shelkov AY, Botikov AG, Erokhova AS, Shcheblyakov DV, Esmagambetov IB, Zubkova OV, Tokarskaya EA, Savina DM, Vereveyko YR, Ungur AS, Naroditsky BS, Ishmukhametov AA, Logunov DY, Gintsburg AL. Tukhvatulin AI, et al. Emerg Microbes Infect. 2022 Dec;11(1):2229-2247. doi: 10.1080/22221751.2022.2119169. Emerg Microbes Infect. 2022. PMID: 36031930 Free PMC article.
41 results